Future Events

The benefits of routine-based ...

Join leading experts for this free webinar on 16 May 2023.

Fever in returning travellers

ISAC is pleased to announce the launch of a second free E-module which has been developed as part of a ...

More info
32nd International Congress of ...

Watch the recording of Plenary 2: Treatment of multidrug resistant Pseudomonas aeruginosa infections by Prof. Juan-Pablo Horcajada

Read more
32nd International Congress of ...

Watch the recording of the opening lecture from the 32nd International Congress of Antimicrobial Chemotherapy (ICC) on "Microbial Theranostics - ...

Read more
E-module: Respiratory tract infections ...

ISAC is pleased to announce the launch of its first e-module which has been created as part of the ISAC ...

Read more
Deciphering the mechanisms of ...

This is the third talk in the series of webinars on "When pharmacometrics and systems pharmacology meet infectious disease" organised ...

Read more

All ISAC webinars are free to attend and free to watch after the event.

COVID-19 Webinar Series

COVID-19: revaccination and variant vaccines

Vaccination against COVID-19 has saved millions of lives so far. But, there are many problems implementing worldwide vaccination such as production, distrubition, cost and vaccine hesitancy issues. Beyond that, at this stage of the pandemic, the world must decide:

• Do we need booster doses?
• Are original vaccines effective or do we need variant vaccines?
• What are those variant vaccines?

Experts in the field will answer these timely and important questions in the next webinar in ISAC’s COVID-19 series on 26 September 2022 at 12.00 (GMT).

Rafael Araos (Research Professor, Institute of Science and Innovation in Medicine, Clínica Alemana Universidad del Desarrollo, Chile)
Revaccination in COVID-19

Eric Gao (Medical Affairs Director, Sinocav Biotect Ltd, China)
Inactivated vaccines

Dr Sultan Abduljawad (Global Scientific Advisor, BioNTech)
mRNA vaccines

Bárbara Emoingt Furtado (Associated Medical Director for Vaccine & Immune Therapies, AstraZeneca, UK)
Vector vaccines

What is Long COVID?

Long COVID, also known as post COVID, is a condition thought to impact millions of patients (as many as 1 in 5).
It can cause post-viral fatigue, lasting organ damage or post-intensive care symptoms, cognitive dysfunction and depression among many other symptoms.
ISAC, together with its international experts, delivered a webinar to explore the pathology, microbiology, immunology and neurology of the condition.

Vanya Gant (University College Hospital, London, United Kingdom)
Immunology changes in Long COVID – preliminary data

Işın Ünal Çevik (Hacettepe University, Faculty of Medicine, Ankara, Turkey)
Clinical aspects - Neuropsychiatry

Itzchak Levy (Chaim Sheba Medical Center, Tel-Hashomer, Israel)
Clinical aspects – General

COVID-19: Effective Treatments

The fourth in this series of ISAC Academy webinars reviewed the evidence on treatments for COVID-19. The three speakers discussed the treatment options and developing scientific evidence around the available treatment modalities. The challenge with treating COVID-19 appears to be managing the range of different pathologies from the initial viraemic insult to the immunological response to the infection.

Prof. Ömrüm Uzun (Hacettepe University, Turkey)
Antiviral Treatment

Prof. Yazdan Yazdanpanah (Paris Diderot University, France)
Convalesvcent plasma and antibody treatment

Prof. Ahmet Gul (Istanbul University, Turkey)
Treatment of Hyperinflammatory Response in COVID-19

COVID-19: Variants

The third webinar in the series looked at COVID-19 variants. As the pandemic has progressed, molecular epidemiology has been an important tool in monitoring the progress of the infection across the world. Novel variants of SARS-CoV2 have been identified and there has been much speculation about the characteristics of these variants in terms of transmissibility, pathogenicity and vaccine escape. This exciting webinar will explore these issues and the role of new virus variants in the development of the pandemic.

Sharon Peacock (COVID-19 Genomics UK (COG-UK) consortium, UK)
Using UK SARS-CoV-2 genomes to evaluate the impact of travel and travel restrictions

Chantal Reusken (Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands)
Molecular epidemiology of SARS-CoV-2. Experience from the Dutch National Institute of Public Health and Environment


The second ISAC webinar reviewed the three major vaccine candidates currently licensed for use. Three experts in their field who are also involved in their national vaccination programmes covered one of the vaccine types. This webinar was suitable for everyone including all infection specialists. The COVID-19 pandemic affects us all and it is important that we understand the new vaccines that are now available. 

Andreas Voss (Radboudumc Center for Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands)

Serhat Unal (Hacettepe University School of Medicine in Ankara, Turkey)
Inactivated vaccine

Kelly Lindert (Arcturus Therapeutics, US)
mRNA Vaccines & a single shot mRNA vaccine

Saul Faust (Southampton NIHR Wellcome Trust Clinical Research Facility, UK)
Astra Zeneca / Oxford vaccine

COVID-19: Around the World in 80+ Minutes

The first in the COVID-19 series brought a global view of the pandemic from those on the front-line in diverse parts of the world. It covered aspects of epidemiology and genomics, screening, control, treatment and consequences of infection. The speakers, all leaders in their fields, have a unique perspective of how the pandemic affects their regions.

Andreas Voss (the Netherlands)
Benedetta Allegranzi (Italy) - the WHO View
Po-Ren Hsueh (Taiwan)
Kazuhiro Tateda (Japan)
Ben Howden (Australia)
Desh Deepak (India)
Serhat Unal (Turkey)
Souha Kanj (Lebanon)
Folsade Ogunsola (Nigeria)
Matthew Dryden (UK)
Mike Bell (USA)
Joana D'arc G. Silva (Brazil)